HOLON, Israel, November 21, 2016 /PRNewswire/ --
Compugen Ltd. (NASDAQ: CGEN, a leading predictive drug discoverycompany, today announced that Dr. Anat Cohen-Dayag, President and Chief Executive Officer of Compugen, will present a corporate introduction and overview at the 28th Annual Piper Jaffray Healthcare Conference in New
Compugen is a leading therapeutic discovery company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class biologics. The primary focus of the Company's current pipeline is on immune checkpoint target candidates discovered by the Company, potentially providing the basis for a next wave of therapeutics for cancer immunotherapy. Compugen's business model is based on selectively entering into collaborations for its novel target candidates and drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Israel, with R&D facilities in Israel and South San Francisco. At the US facilities, monoclonal antibody therapeutic candidates are discovered and developed against the Company's novel target candidates. For additional information, please visit Compugen's corporate website at http://www.cgen.com.
Company contact: Tsipi Haitovsky Global Media Liaison Compugen Ltd. Email: firstname.lastname@example.org Tel: +972-52-598-9892
SOURCE Compugen Ltd.
Subscribe to our Free Newsletters!